Concepts (125)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hemophilia A | 14 | 2023 | 28 | 3.630 |
Why?
|
| Factor VIII | 9 | 2023 | 20 | 2.040 |
Why?
|
| Coagulants | 4 | 2020 | 5 | 1.150 |
Why?
|
| Hemorrhage | 6 | 2023 | 30 | 0.960 |
Why?
|
| Antibodies, Neutralizing | 4 | 2018 | 11 | 0.960 |
Why?
|
| Isoantibodies | 3 | 2018 | 6 | 0.920 |
Why?
|
| Polyethylene Glycols | 1 | 2020 | 10 | 0.630 |
Why?
|
| Health Literacy | 1 | 2021 | 45 | 0.630 |
Why?
|
| Physicians | 1 | 2020 | 43 | 0.610 |
Why?
|
| Patient Satisfaction | 1 | 2020 | 118 | 0.580 |
Why?
|
| Mutation | 1 | 2018 | 175 | 0.510 |
Why?
|
| Humans | 21 | 2023 | 12240 | 0.400 |
Why?
|
| Factor VIIa | 3 | 2017 | 4 | 0.400 |
Why?
|
| Hemophilia B | 3 | 2017 | 6 | 0.400 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2018 | 182 | 0.370 |
Why?
|
| Fibrinolysis | 2 | 2013 | 2 | 0.360 |
Why?
|
| Recombinant Proteins | 4 | 2017 | 90 | 0.360 |
Why?
|
| Male | 14 | 2021 | 6815 | 0.360 |
Why?
|
| Hemarthrosis | 4 | 2021 | 14 | 0.350 |
Why?
|
| Fibrinolysin | 1 | 2011 | 1 | 0.340 |
Why?
|
| Thrombin | 1 | 2011 | 12 | 0.330 |
Why?
|
| Blood Coagulation | 1 | 2011 | 11 | 0.330 |
Why?
|
| Young Adult | 7 | 2021 | 863 | 0.280 |
Why?
|
| Surveys and Questionnaires | 2 | 2021 | 546 | 0.270 |
Why?
|
| Adolescent | 7 | 2021 | 989 | 0.260 |
Why?
|
| Child, Preschool | 6 | 2017 | 320 | 0.260 |
Why?
|
| Risk Assessment | 1 | 2017 | 295 | 0.240 |
Why?
|
| Adult | 7 | 2020 | 3557 | 0.230 |
Why?
|
| Time Factors | 3 | 2018 | 695 | 0.200 |
Why?
|
| Pilot Projects | 2 | 2021 | 214 | 0.190 |
Why?
|
| Phenotype | 3 | 2018 | 157 | 0.180 |
Why?
|
| United States | 3 | 2020 | 989 | 0.170 |
Why?
|
| Child | 5 | 2016 | 614 | 0.170 |
Why?
|
| Quality of Life | 2 | 2020 | 261 | 0.170 |
Why?
|
| Treatment Outcome | 3 | 2018 | 1478 | 0.170 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2020 | 17 | 0.160 |
Why?
|
| Israel | 1 | 2020 | 7 | 0.160 |
Why?
|
| Risk Factors | 2 | 2018 | 1049 | 0.160 |
Why?
|
| Netherlands | 1 | 2020 | 23 | 0.160 |
Why?
|
| Middle Aged | 5 | 2020 | 4043 | 0.160 |
Why?
|
| Hodgkin Disease | 1 | 2009 | 9 | 0.150 |
Why?
|
| Attitude of Health Personnel | 1 | 2020 | 66 | 0.150 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2009 | 18 | 0.150 |
Why?
|
| Positron-Emission Tomography | 1 | 2009 | 36 | 0.150 |
Why?
|
| Severity of Illness Index | 2 | 2018 | 423 | 0.150 |
Why?
|
| Sickle Cell Trait | 1 | 2018 | 1 | 0.140 |
Why?
|
| Television | 1 | 2018 | 2 | 0.140 |
Why?
|
| Female | 6 | 2020 | 6974 | 0.140 |
Why?
|
| Information Dissemination | 1 | 2018 | 8 | 0.140 |
Why?
|
| Genetic Testing | 1 | 2018 | 29 | 0.140 |
Why?
|
| Sports Medicine | 1 | 2018 | 17 | 0.140 |
Why?
|
| South America | 1 | 2018 | 2 | 0.140 |
Why?
|
| Asia | 1 | 2018 | 6 | 0.140 |
Why?
|
| Africa | 1 | 2018 | 7 | 0.140 |
Why?
|
| North America | 1 | 2018 | 14 | 0.140 |
Why?
|
| Europe | 1 | 2018 | 21 | 0.140 |
Why?
|
| Athletes | 1 | 2018 | 30 | 0.140 |
Why?
|
| DNA Mutational Analysis | 1 | 2018 | 30 | 0.140 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2009 | 281 | 0.140 |
Why?
|
| Social Media | 1 | 2018 | 32 | 0.130 |
Why?
|
| Prothrombin | 1 | 2017 | 4 | 0.130 |
Why?
|
| Anticoagulants | 2 | 2015 | 42 | 0.130 |
Why?
|
| Predictive Value of Tests | 1 | 2018 | 218 | 0.130 |
Why?
|
| Lung Neoplasms | 1 | 2009 | 247 | 0.130 |
Why?
|
| von Willebrand Factor | 1 | 2016 | 5 | 0.120 |
Why?
|
| Aged | 3 | 2020 | 4000 | 0.120 |
Why?
|
| Hematology | 1 | 2016 | 2 | 0.120 |
Why?
|
| Career Choice | 1 | 2016 | 13 | 0.120 |
Why?
|
| Physicians, Women | 1 | 2016 | 11 | 0.120 |
Why?
|
| Physician Executives | 1 | 2016 | 7 | 0.120 |
Why?
|
| Blood Coagulation Tests | 2 | 2016 | 4 | 0.110 |
Why?
|
| Leadership | 1 | 2016 | 55 | 0.110 |
Why?
|
| Infant | 3 | 2016 | 277 | 0.110 |
Why?
|
| Venous Thrombosis | 1 | 2015 | 21 | 0.110 |
Why?
|
| Factor VII Deficiency | 1 | 2013 | 1 | 0.100 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2017 | 128 | 0.090 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2017 | 179 | 0.090 |
Why?
|
| Proportional Hazards Models | 2 | 2016 | 161 | 0.090 |
Why?
|
| Joint Diseases | 1 | 2011 | 44 | 0.080 |
Why?
|
| Half-Life | 2 | 2023 | 7 | 0.080 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 1 | 2009 | 2 | 0.080 |
Why?
|
| Vena Cava, Inferior | 1 | 2009 | 4 | 0.080 |
Why?
|
| Death, Sudden | 1 | 2009 | 5 | 0.080 |
Why?
|
| Constriction, Pathologic | 1 | 2009 | 10 | 0.080 |
Why?
|
| Testicular Neoplasms | 1 | 2009 | 12 | 0.080 |
Why?
|
| Headache | 2 | 2017 | 22 | 0.060 |
Why?
|
| Survival Analysis | 1 | 2017 | 99 | 0.060 |
Why?
|
| Area Under Curve | 2 | 2017 | 39 | 0.060 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2016 | 47 | 0.060 |
Why?
|
| Cohort Studies | 1 | 2016 | 827 | 0.050 |
Why?
|
| Patients | 1 | 2023 | 16 | 0.050 |
Why?
|
| Prospective Studies | 2 | 2017 | 817 | 0.050 |
Why?
|
| Subtraction Technique | 1 | 2009 | 1 | 0.040 |
Why?
|
| Radiopharmaceuticals | 1 | 2009 | 27 | 0.040 |
Why?
|
| Newspapers as Topic | 1 | 2018 | 1 | 0.030 |
Why?
|
| Retrospective Studies | 1 | 2023 | 1467 | 0.030 |
Why?
|
| Metabolic Clearance Rate | 1 | 2017 | 3 | 0.030 |
Why?
|
| Dizziness | 1 | 2017 | 9 | 0.030 |
Why?
|
| Cross-Over Studies | 1 | 2017 | 24 | 0.030 |
Why?
|
| Injections, Subcutaneous | 1 | 2016 | 12 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2016 | 84 | 0.030 |
Why?
|
| ROC Curve | 1 | 2016 | 78 | 0.030 |
Why?
|
| History, 21st Century | 1 | 2016 | 13 | 0.030 |
Why?
|
| History, 20th Century | 1 | 2016 | 18 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2016 | 76 | 0.030 |
Why?
|
| Colorado | 1 | 2015 | 2 | 0.030 |
Why?
|
| Florida | 1 | 2015 | 2 | 0.030 |
Why?
|
| Endpoint Determination | 1 | 2015 | 12 | 0.030 |
Why?
|
| Single-Blind Method | 1 | 2015 | 46 | 0.030 |
Why?
|
| Observer Variation | 1 | 2015 | 47 | 0.030 |
Why?
|
| Quality Assurance, Health Care | 1 | 2015 | 18 | 0.030 |
Why?
|
| Diagnostic Imaging | 1 | 2015 | 43 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2015 | 113 | 0.030 |
Why?
|
| Recurrence | 1 | 2015 | 126 | 0.030 |
Why?
|
| Incidence | 1 | 2016 | 338 | 0.030 |
Why?
|
| Research Design | 1 | 2015 | 79 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2015 | 324 | 0.030 |
Why?
|
| Synovitis | 1 | 2011 | 14 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2013 | 400 | 0.020 |
Why?
|
| Models, Molecular | 1 | 2011 | 44 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 2009 | 53 | 0.020 |
Why?
|
| Vascular Diseases | 1 | 2009 | 25 | 0.020 |
Why?
|
| Autopsy | 1 | 2009 | 174 | 0.020 |
Why?
|
| Mice | 1 | 2011 | 760 | 0.020 |
Why?
|
| Animals | 1 | 2011 | 2092 | 0.020 |
Why?
|